United Therapeutics Stock Today

UTHR Stock  USD 243.27  4.59  1.85%   

Performance

9 of 100

 
Low
 
High
OK

Odds Of Distress

Less than 2

 
100  
 
Zero
Very Low
United Therapeutics is selling at 243.27 as of the 28th of March 2024; that is -1.85 percent down since the beginning of the trading day. The stock's lowest day price was 236.07. United Therapeutics has a very small chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for United Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
17th of June 1999
Category
Healthcare
Classification
Health Care
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. The company has 47.06 M outstanding shares of which 1.92 M shares are at this time shorted by private and institutional investors with about 3.1 trading days to cover. More on United Therapeutics

Moving together with United Stock

  0.74MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr
  0.73MDWD Mediwound Financial Report 4th of June 2024 PairCorr

Moving against United Stock

  0.83TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
  0.77KA Kineta Inc Report 29th of March 2024 PairCorr
  0.74MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.59MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.51VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
  0.48DBVT DBV Technologies Financial Report 2nd of May 2024 PairCorr
  0.43MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr

United Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. United Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding United Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, United Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to United Therapeutics' managers, analysts, and investors.
Environment Score
Governance Score
Social Score
CEORoger Jeffs
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, SP Midcap 400, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal Testing
Average Analyst Recommendation
Analysts covering United Therapeutics report their recommendations after researching United Therapeutics' financial statements, talking to executives and customers, or listening in on United Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering United Therapeutics. The United consensus assessment is calculated by taking the average forecast from all of the analysts covering United Therapeutics.
Financial Strength
Based on the key indicators related to United Therapeutics' liquidity, profitability, solvency, and operating efficiency, United Therapeutics is performing exceptionally good at this time. It has a great odds to report excellent financial results in April. Financial strength of United Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.290.3248
Moderately Down
Pretty Stable
Total Current Liabilities844.6 M804.4 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total269.4 M377.8 M
Way Down
Slightly volatile
Total Assets7.5 B7.2 B
Sufficiently Up
Slightly volatile
Total Current Assets3.7 B3.6 B
Sufficiently Up
Slightly volatile
United Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to United Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand United Therapeutics' financial leverage. It provides some insight into what part of United Therapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on United Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how United Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
United Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 700 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. United Therapeutics has a current ratio of 7.94, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist United Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, United Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like United Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for United to invest in growth at high rates of return. When we think about United Therapeutics' use of debt, we should always consider it together with cash and equity.

Total Cash From Operating Activities

1.03 Billion
United Therapeutics (UTHR) is traded on NASDAQ Exchange in USA. It is located in 1000 Spring Street, Silver Spring, MD, United States, 20910 and employs 1,168 people. United Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 11.45 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate United Therapeutics's market, we take the total number of its shares issued and multiply it by United Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. United Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 47.06 M outstanding shares of which 1.92 M shares are at this time shorted by private and institutional investors with about 3.1 trading days to cover. United Therapeutics currently holds about 2.26 B in cash with 978 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 49.55.
Check United Therapeutics Probability Of Bankruptcy
Ownership Allocation
United Therapeutics shows a total of 47.06 Million outstanding shares. The majority of United Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in United Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in United Therapeutics. Please pay attention to any change in the institutional holdings of United Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check United Ownership Details

United Stock Price Odds Analysis

In regard to a normal probability distribution, the odds of United Therapeutics jumping above the current price in 90 days from now is under 4%. The United Therapeutics probability density function shows the probability of United Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days United Therapeutics has a beta of -0.0013. This usually implies as returns on benchmark increase, returns on holding United Therapeutics are expected to decrease at a much lower rate. During the bear market, however, United Therapeutics is likely to outperform the market. Additionally, united Therapeutics has an alpha of 0.1442, implying that it can generate a 0.14 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 243.27HorizonTargetOdds Above 243.27
96.41%90 days
 243.27 
3.54%
Based on a normal probability distribution, the odds of United Therapeutics to move above the current price in 90 days from now is under 4 (This United Therapeutics probability density function shows the probability of United Stock to fall within a particular range of prices over 90 days) .

United Stock Institutional Holders

Institutional Holdings refers to the ownership stake in United Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of United Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing United Therapeutics' value.
InstituionRecorded OnShares
Aqr Capital Management Llc2023-12-31
551.8 K
Nuveen Asset Management, Llc2023-12-31
491.5 K
Farallon Capital Management, L.l.c.2023-12-31
476 K
Morgan Stanley - Brokerage Accounts2023-12-31
459.7 K
Norges Bank2023-12-31
457.1 K
Fuller & Thaler Asset Management Inc2023-12-31
431.1 K
Palo Alto Investors, Llc2023-12-31
395.8 K
Orbimed Advisors, Llc2023-12-31
386.1 K
Lsv Asset Management2023-12-31
377.4 K
Blackrock Inc2023-12-31
5.3 M
Vanguard Group Inc2023-12-31
4.7 M
View United Therapeutics Diagnostics

United Therapeutics Historical Income Statement

United Therapeutics Income Statement is one of the three primary financial statements used for reporting United's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of United Therapeutics revenue and expense. United Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, United Therapeutics' Income Before Tax is relatively stable compared to the past year. As of 03/28/2024, Net Income is likely to grow to about 1 B, while Total Operating Expenses is likely to drop slightly above 469.6 M. View More Fundamentals

United Stock Against Markets

Picking the right benchmark for United Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in United Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for United Therapeutics is critical whether you are bullish or bearish towards United Therapeutics at a given time. Please also check how United Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in United Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Optimization Now

   

Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
All  Next Launch Module

United Therapeutics Corporate Directors

United Therapeutics corporate directors refer to members of an United Therapeutics board of directors. The board of directors generally takes responsibility for the United Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of United Therapeutics' board members must vote for the resolution. The United Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Christopher CauseyIndependent DirectorProfile
Richard GiltnerIndependent DirectorProfile
Katherine KleinDirectorProfile
Raymond DwekNon-Independent DirectorProfile

How to buy United Stock?

Before investing in United Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in United Therapeutics. To buy United Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of United Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase United Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located United Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased United Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as United Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy United Stock please use our How to Invest in United Therapeutics guide.

Already Invested in United Therapeutics?

The danger of trading United Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of United Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than United Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile United Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.
Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for United Stock analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.626
Earnings Share
19.8
Revenue Per Share
49.733
Quarterly Revenue Growth
0.251
Return On Assets
0.1122
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.